• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Emixustat

CAS No. 1141777-14-1

Emixustat ( ACU-4429 )

产品货号. M10502 CAS No. 1141777-14-1

Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
50MG ¥8068 有现货
100MG ¥14094 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Emixustat
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.
  • 产品描述
    Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM; reduces the production of visual chromophore (11-cis retinal) in wild-type mice following a single oral dose (ED50 = 0.18 mg/kg).Other Indication Phase 3 Clinical
  • 同义词
    ACU-4429
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Other Targets
  • 研究领域
    Other Indications
  • 适应症
    Other Disease

化学信息

  • CAS Number
    1141777-14-1
  • 分子量
    263.38
  • 分子式
    C16H25NO2
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO: ≥ 43 mg/mL
  • SMILES
    C1CCC(CC1)COC2=CC=CC(=C2)C(CCN)O
  • 化学全称
    Benzenemethanol, α-(2-aminoethyl)-3-(cyclohexylmethoxy)-, (αR)-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Kiser PD, et al. Nat Chem Biol. 2015 Jun;11(6):409-15.
2. Bavik C, et al. PLoS One. 2015 May 13;10(5):e0124940.
3. Zhang J, et al. J Clin Invest. 2015 Jul 1;125(7):2781-94.
产品手册
关联产品
  • Methyl nomilinate

    Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.

  • Justicidin A

    Justicidin A is a type of bioactive chemical from Justica procumbens.

  • Dehydrojuncusol

    Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.